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Radiotherapy can effectively kill malignant cells, but the doses required to cure cancer patients
can often not be applied as they come at the cost of severe collateral damage to adjacent healthy tis-
sues. Hyperthermia (HT) is a promising option to improve the outcome of radiation treatment (RT)
and is increasingly applied in the clinics by incorporating a broad range of technological advances
over the past 15 years. However, the design of adequate HT treatment scheduling in the clinical set-
ting has remained challenging. From the theoretical perspective, mathematical models to predict the
proposed synergistic effect and therapeutic outcome of combined treatment schemes are essential to
improving treatment outcomes. We here propose a theoretical model to better understand the thermal
enhancement of RT. In our model, the thermal enhancement ratio (TER) is explained by the fraction
of cells that is radiosensitised by the infliction of sublethal damage through mild HT. In the course of
further damage, the cells finally lose proliferative capacity and die, respectively, in a non-reversible
process. We suggest the TER to be proportional to the energy invested in the sensitisation, which is
modelled as a simple rate process. Assuming protein denaturation as the main driver of HT-induced
sublethal damage and considering the temperature dependence of the heat capacity of cellular pro-
teins, the sensitisation rates were found to depend exponentially on temperature; this is in agreement
with previous empirical observations. Accordingly, our theoretical calculations well reproduce ex-
perimental data from both in-vitro and in-vivo studies for the simultaneous application of mild HT
and RT. Our model is able to predict and explain the thermal modulation of cellular radioresponse.
Ongoing systematic experimental studies, and calorimetry measurements, shall further validate our
predictions for other cell models.
INTRODUCTION
Despite considerable efforts for decades towards
the improvement of early diagnosis and therapy,
cancer has remained a serious global health problem,
with 18.1 million new cases and 9.6 million cancer
deaths reported worldwide, just in 2018 [1]. Since
the 1980s, mild hyperthermia (heating tumour tissue
to 40.0 - 42.5 ◦C for ∼ 1 h) is known to enhance
the therapeutic outcomes in cancer patients, when
combined with radio-, chemo- and/or immunother-
apy [2, 3]. Technological improvements in medical
heating, imaging and non-invasive thermometry
over the past decade have revived hyperthermia
treatment (HT) as a precision cancer therapy [3–6],
particularly when used in combination with ionizing
radiation. The number of ongoing HT clinical
trials, either alone or in combination with different
treatment modalities, evidences the increasing use
of therapeutic HT (467 still ongoing clinical trials
out of 1198 since 2000) [7]. Radiotherapy (RT) is
supposedly a curative treatment modality, but the
radiation dose required to eradicate all cancer cell
subpopulations in a tumour can often not be applied
due to severe acute or long-term side effects, which
include radiation-induced tissue fibrosis and second
malignancies [8]. Hyperthermia is known to be one
of the most potent radiosensitisers [9–13], meaning
that less radiation is required to achieve the same
local tumour cell kill, thereby reducing the adverse
effects of radiation in the adjacent normal tissues
[14, 15].
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2Different theoretical and practical problems
still need to be solved in order to implement com-
bined HT+RT therapy in routine clinical practice
worldwide [13]. From the theoretical perspective,
mathematical models to predict the therapeutic
outcome of combined treatment schemes are es-
sential for a better understanding of the synergistic
effect, and also for the design of adequate treatment
scheduling in the clinical setting [16]. Several
mathematical models for individual RT and HT
have been proposed, but there is poor consensus
when it comes to the efficacy of combined treat-
ment regimes. For RT, the LQ-model is the most
extensively used approach to predict the effect of
irradiation on cell populations [17, 18]. This model
describes the surviving fraction of cells as a function
of the applied radiation dose DR by means of two
main variables, called “radiological parameters” α
and β [18]. In the context of radiobiology, “survival”
means the conservation of the cell’s proliferative
capacity [19] (see definitions box). Regarding
HT, there is considerable literature describing the
impact of heat on different cellular components
[20–24], and several models are aimed to predict
the survival of cells under HT treatments [25]. For
thermal-radiosensitisation using temperatures of
40-46 ◦C, there is a general agreement on a relevant
role of DNA repair impairment by heat-induced
protein denaturation in the processes of radiosensi-
tisation between 40-46 ◦C [9–11, 17, 21, 22, 26].
The majority of previous approaches to model the
combined efficacy of hyperthermia and radiation
on mammalian cells have implemented the thermal
effects in the LQ-model by proposing empirical
temperature dependencies for the radiological
parameters [27–29], but the physical principles and
the detailed mechanisms underlying this empirical
dose-lowering concept are still elusive [26]. The link
between modelling concepts and plausible mecha-
nistic explanations still needs to be established to
serve as a more reliable framework for predictions.
Here, we propose a survival model for the si-
multaneous application of HT and RT that provides
insights from a thermodynamic perspective. In our
model, the modulation of the radiological parame-
ters arises directly from the definition of the thermal
enhancement ratio (TER). It compares the radiation
dose required to achieve a specific endpoint with
ionizing radiation alone (DR), e.g. surviving fraction
of cells or tumour control probability, and the radi-
ation dose required to achieve the same endpoint in
combination with hyperthermia (DR+H) TER = DRDR+H
[30]. We propose the enhancement to be a rate lim-
iting process, proportional to the energy invested
in sensitising a cell to die. Our approach presents
a theoretical basis to understand how hyperthermia
results in radiosensitisation, a process that depends
on treatment time and temperature. Our findings are
consistent with previous experimental studies in the
range of RT combined with mild hyperthermia.
Definitions box
The key biological terms used in this work
have been specified as follows:
 Cell kill (“dead state”): From the radiobiolog-
ical perspective, a cell is considered to be dead
(killed) when it loses its proliferative capacity, i.e.
is no longer able to divide (becomes replication-
incompetent). This encompasses not only cells
losing their membrane integrity and truly dying
(by apoptosis, necrosis, or other), but also living
cells undergoing terminal differentiation, perma-
nent cell cycle arrest or senescence. This type of
cell kill leads to control of the malignant disease,
independent of the underlying process.
Cell survival (“alive state”): A cell is con-
sidered to survive if it remains replication-
competent, i.e. retains its proliferative capacity
after the treatment.
Cell damage: Any type of deterioration of the
cellular processes, regardless of origin, that ad-
vances the cell towards the dead state.
 Radiological parameters α and β: They char-
acterize the radiosensitivity of cells or tumours.
-α Characterizes the initial slope of logarithmic
survival curves. It is associated to the mean num-
ber of DNA double strand breaks produced with a
single radiation event [31].
-β Characterizes the shoulder of logarithmic sur-
vival curves. It is associated to the mean num-
ber of DNA double strand breaks produced with
two radiation events, i.e. two independent single
strand breaks in close proximity that lead to for-
mation of a double strand break [31].
-α/β ratio Quantifies radiation sensitivity of tis-
sue. The higher the ratio, the lower the sensitivity.
 Thermal enhancement ratio (TER): Ratio be-
tween the radiation dose required to achieve a spe-
cific endpoint with ionizing radiation alone, and
the radiation dose required to achieve the same
endpoint in combination with hyperthermia.
3RESULTS AND DISCUSSION:
Mathematical model for the outcome of
simultaneous HT+RT
In the following we describe our theoretical
model and its correspondence with two different
types of experimental data sets from mammalian
cell models, in-vitro and in-vivo, in the range of mild
HT published in the last century. These seminal
studies were chosen because, to our knowledge, they
are the only studies which compile complete sets of
thermal enhancement ratios, systematically obtained
for several temperatures and treatment times in the
HT regime. One set of data was collected in course
of an in-vitro 2D culture study in Chinese hamster
ovary (CHO) cells [32], the other was derived from
animal experiments with C3H murine mammary
carcinoma xenografts [33].
Hyperthermia affects the radiation dose-response
curve
The LQ-model for radiotherapy predicts the
surviving fraction of cells as an exponential function
of the radiation dose, S (DR) = exp
{
−(αDR + βD2R)
}
[18]. When HT is applied in combination with RT
the parameters α and β are modulated by both the
temperature T , and the application time t of heat
[37]. As a result, the sensitivity of cells to RT is
increased and the radiation dose DR+H required to
produce the same surviving fraction is lower. HT
affects the survival probability curves in three ways:
1. the curves are shifted down as a consequence
of cell killing from HT itself (offset at DR = 0),
2. there is a steeper initial slope (α), and 3. the
shoulder of the curve (β) is changed as illustrated in
Fig.1. In this work, the term “cell kill” is defined as
the complete loss of proliferative capacity of a cell,
regardless its membrane integrity.
The most accepted hypothesis for the radiosen-
sitising effect of HT assumes the heat-induced
denaturation of repair proteins impairs the DNA
repair process upon irradiation [15, 26]. In the
LQ-model hyperthermia mainly affects β, which is
supposedly related to repairable DNA single-strand
breaks (SSB), and the HT-induced sensitisation is
generally associated with inhibition of DNA repair
[16]. Nevertheless, this description is incomplete
because the change in α is not negligible. Given
that β is not exclusively related to pairs of SSB but
also to clusters of DNA lesions [18], we propose to
differentiate between repairable and sublethal DNA
damage, which are not necessarily the same. We
suggest to extend the hypothesis of repair inhibition
to a more general explanation based on sublethal
damage accumulation (whether reversible or not), to
better understand the synergy between radiation and
thermal energy when applied to biological tissue.
Modulation of α and β by HT as a function of TER
A portion of the thermal energy of HT goes
into direct cell killing and another portion into
radiosensitisation. For HT used for combinatorial
therapy (40-46 ◦ C) only a minor fraction relates to
direct cell-killing.
We therefore propose that the radiosensitising
portion of the energy is invested in the accumulation
of sublethal damage, facilitating radiation-induced
cell death. In our model hyperthermia causes the
cells to advance from an original undamaged state
(A) to a more damaged state (A’) in the sequence
of sublethal damage (SLD) accumulation, as is illus-
trated in Fig. 1(c). Starting from (A’) instead of (A),
the radiation energy required to produce lethal and
sublethal transitions is reduced, and hence, α and β
are effectively rescaled to α∗ and β∗. Further, we as-
sume that this modulation comes directly from the
definition of the TER, in such a way that the new pa-
rameter (α∗ and β∗) become treatment-time and tem-
perature dependent (see Methods section for details)
α∗(T, t) = α ∗ TER (1)
β∗(T, t) = β ∗ TER2. (2)
Thermodynamic basis of TER
TER is expected to be proportional to the ther-
mal energy absorbed by the cell, which is invested
in the transition from (A) to (A’) (transition towards
’dead’state’). We propose this energy to increase lin-
early with the time of heat exposure t, and with the
rate of energy absorption kE(T ). In a simplified ver-
sion of the SLD accumulation induced by hyperther-
mia, the step from (A) to (A’) is represented by a
single rate process, with a net rate of transition k(T )
4Figure 1. left: Schematic survival probabilities for the three cases depicted on the right. (a) Cell killing as a single
rate process with transition rate from alive (A) to dead (D) α. (b) Two-step cell killing process in the LQ-model for
radiation. A cell transits from the alive state (A) to the dead state (D) through two possible paths: α for direct killing
(a single hit suffices to kill), and β for indirect killing (when two hits are required to kill). (c) Combined HT+RT:
HT-induced damage elevates cells from state (A) to an activated state (A’), effectively reducing the α/β ratio. Since
β is more efficiently reduced, the direct path α dominates the killing process and consequently reduces the survival
probability.
(proportional to the rate of energy absorption) as de-
picted in Fig. 1(c) and expressed by
TER = o + a tk(T ). (3)
Here, o is the onset of the thermal enhancement
ratio, which should converge to one for no HT treat-
ment (t = 0); a is a parameter that accounts for the
tumour size (or the amount of malignant cells) and
the intrinsic sensitivity of the cells to RT and HT,
and k(T ) is the temperature-dependent rate of the
sensitisation process. Based on the thermodynam-
ics of protein denaturation, we found the transition
rate of this process to increase exponentially with in-
creasing temperature k(T ) = c eb(T−Tg) (see methods
section for details of the model). In this equation,
c and b are cell-type dependent parameters and Tg
is the dominant transition temperature, i.e. the av-
erage melting point of cellular proteins undergoing
denaturation. We achieve this theoretical prediction
by considering the change of the heat capacity of the
proteins as a linear function of the temperature, and
not as a constant value as usually assumed in Arrhe-
nius kinetics. The heat capacity of cellular proteins
displays a Lorentzian-type function of the tempera-
ture [20–24], which can be approximated at first or-
der as linear functions in the vicinity of the melting
point [34, 35]. Remarkably, the melting point Tg in
both cases has good correspondence to the calorime-
try studies performed by Lepock and collaborators
[20, 21] where they found the melting point in the
mild-hyperthermia treatment to be in the range of
45 − 48◦C for different mammalian cells. Plugging
the obtained transition rate into Eq.3, the TER reads
TER = o + a′t eb(T−Tg), (4)
with a′ = ac for simplicity. This model predicts
exponential increase of α∗ and β∗ with temperature,
which is much more pronounced for β∗. These
predictions are consistent with experimental results
in cell cultures [32, 36], and data from human
clinical trials [16, 37].
5Radiosensitising effects are also reflected and
quantified by reductions in the α/β ratio, which is
basically higher for intrinsically more radioresistant
cells [16, 18]. For the combined RT+HT scheme
the α/β ratio is reduced as a consequence of the
enhancement of the sublethal damage over the direct
damage. The ratio for the combined treatment then
reads α∗/β∗ = α/βTER .
Predictions of experimental data from literature
We tested the performance of our model (Eq.4)
on two types of experimental data. One dataset
was recorded in in-vitro 2D cell culture experiments
(CHO cell line) [32], and the other one derived from
an in-vivo animal study (C3H mammary carcinoma
tumour xenograft mouse model) [33]. We found that
our model well predicts the outcome of these stud-
ies. As shown in Fig. 2(a) and (c), both datasets dis-
play a linear dependency of the TER with treatment
time t for all tested temperatures, indicating a rate-
dependent behaviour of the function. The slope of
each linear function is proportional to a temperature-
dependent rate, matching the exponential fit shown
in Fig.2(b) and (d) respectively. The parameters and
the respective coefficients of determination R2 are
summarized in Table I for both examples.
Table I. Parameters of the TER model Eq.4
Cell model o a′ b Tg[◦C] R2
CHO (in vitro) 0.97 ±0.03 1.00 0.95 48.07 0.978
C3H (in vivo) 1.07 ±0.04 1.00 0.86 46.80 0.993
All model parameters were obtained from fitting
of the radiation response curves, given the existence
of complete data sets where RT is combined with
HT at different temperatures and treatment times.
We must stress that this linear model is valid in the
regime of mild HT (40-46 ◦C), which is used for
radiosensitisation purposes at which heat-induced
damage is primarily sublethal [22, 38].
As can be seen in table I, the melting temper-
ature is different for CHO (in-vitro) and C3H (in-
vivo). This result is consistent with the findings from
Lepock and collaborators that show different melt-
ing points for distinct cell types [22]. However, the
other parameters of the model turn out to be similar
for the two data sets. The parameter related to the
number of cells (a′ = ac) is equal to one for these
two very different tumour cell models (monolayer
culture and xenograft). Given the current lack of ex-
perimental data, i.e. for other tumour models, one
could speculate that the slope in equation 4 is com-
pletely modelled by the exponential factor. This fac-
tor is solely a function of the thermodynamic quan-
tities describing the heat capacity, namely the melt-
ing point Tg and the slope of the calorimetry peak
B (b = B/2kB). Remarkably, this calorimetry peak
is also very similar for the two tumour cell mod-
els with distinct levels of complexity included in the
present study. Hence, a′ and b could be modelled
using generalised values. This should be verified by
meticulous future experimental work. Calorimetry
assays together with systematic TER measurements
in various tumour cell models will be particularly
relevant in this context, and can lead to a consider-
able reduction in the number of adjustable parame-
ters. Nonetheless, our model already quite well pre-
dicts and explains from thermodynamic principles
the modulation of radioresponse caused by HT treat-
ment with at most three adjustable parameters.
CONCLUSIONS AND PERSPECTIVES
In this work, we have proposed the enhancement
of radiotherapy by hyperthermia as the result of
the increased vulnerability of a cell. It is achieved
by the accumulation of sublethal damage either re-
pairable or not. In our model, the radiosensitisation,
quantified by TER, is proportional to the energy
invested to induce this damage. We propose that
in the range of mild HT, this energy and therefore
the synergistic effect measured by TER, is a rate-
dependent process that increases linearly with the
time of heat application. We found the rate of the
process to increase exponentially with temperature
as a result of the chemical reactions involved in
the protein denaturation process, which is induced
by HT. This model offers a thermodynamics based
approach to explain experimental results previously
obtained in different studies.
Our model is based on the modulation of the
radiobiological parameters of the LQ-model, which
is suitable to reproduce the survival curves of cell
cultures. To extend the applicability of survival
models, translation into more relevant clinical
6(b) Natural logarithm of the slope(a) Thermal enhancement ratio - CHO cells
(d) Natural logarithm of the slope(c) Thermal enhancement ratio - C3H in-vivo
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Figure 2. (a) and (c) show the linear dependency of the thermal enhancement ratio (TER) on time of exposure for
CHO cells in vitro and C3H mammary carcinoma cells in mice xenografts in vivo,respectively. The slope of the linear
fitting clearly depends on the temperature of the hyperthermia treatment, and the natural logarithm of the slope was
plotted as a function of temperature for both datasets in (b) and (d). The linear trend lines show the exponential
behaviour of the temperature dependent rate k(T ) according to Eq.10.
outcomes such as tumor control probabilities or
control doses is required, where “control” means
the extinction of replication-competent tumour cells
at the end of treatment [19]. This translation is
usually done by means of simple logistic functions,
which have been found to insufficiently estimate
radiation responsiveness [39, 40]. More accurate
translations require more elaborated approaches in
order to reflect the treatment response in a more
realistic and complex in vivo-like environment. Ex-
amples of factors that would need to be considered
include cell-cell interactions, oxygen distributions,
proliferative capacity and cell cycle progression in a
3-D cellular context. We next intend to combine the
present theoretical findings with cellular automaton
simulations, to model the treatment outcome in
in-silico multicellular tumour spheroids.
Here, we present a model which describes, pre-
dicts, and explains relevant aspects of the thermal
enhancement of RT in the case of simultaneous ap-
plication. Nevertheless, sequential combination of
HT and RT is used more frequently in the clinics for
practical reasons, although it is considered to be less
effective than simultaneous treatment. Therefore,
from a theoretical perspective, a complementary ap-
proach that also works for both individual treatments
(HT or RT) and for sequential therapy needs to be
7developed. The present study paves the ground for a
more elaborate unified model, which describes from
common general principles the individual treatments
and their sequential application (including the order
of and the time elapsed between treatments). This
approach will also constitute the focus of a forthcom-
ing work.
METHODS
Thermal enhancement of radiotherapy
When a certain radiation dose DR is applied to a
set of living cells, the reduction rate is proportional
to the number of cells at the time of the treatment
dN
dDR
= −αN. (5)
Therefore, the direct transition from the alive
state of the cell to the dead state obeys an expo-
nential behavior S = e−αDR , where S = N/N0 is
the survival fraction, and α defines the transition rate
per dose, as depicted in Fig.1(a) [18]. If the killing
effect is composed of a direct killing path α, and a
secondary path composed of two or more stages of
sublethal damage (SLD) accumulation, the logarith-
mic survival curve acquires a shoulder, as depicted in
Fig.1(b). In the particular case of the LQ-model, the
exponent has a linear and a quadratic contribution,
corresponding to direct killing and SLD accumula-
tion respectively
− ln(S ) = αDR + βD2R . (6)
The LQ-model was originally employed as an em-
pirical approach [41]; later Chadwick and Leenhouts
[31] proposed a molecular interpretation based on a
statistical approach. In their interpretation cell death
occurs due to double-strand breaks (DSB) of DNA,
such that α and β account for the probability of pro-
ducing irreparable DSB as a consequence of one or
two photon/particle hits, respectively. As a conse-
quence of the sensitisation effect of HT, the radiation
dose DR+H required to produce the same surviving
fraction is reduced. This reduction implies in Eq.6,
that α and β are increased to α∗ and β∗ (in order to
obtain the same therapeutic outcome), assessing the
increased sensitivity of the cells as a consequence of
heat
− ln(S ) = α∗DR+H + β∗D2R+H . (7)
This radiosensitising effect of hyperthermia is
quantified by the thermal enhancement ratio TER.
It is defined as the ratio between the radiation dose
required to achieve a specific endpoint with ionizing
radiation alone (DR), and the radiation dose result-
ing in the same endpoint value when combined with
hyperthermia (DR+H):
TER =
DR
DR+H
, (8)
with DR > 0 and DR+H > 0. The new linear and
quadratic coefficients of the LQ-model are obtained
by replacing DR with DR+HTER in Eq.6:
− ln(S ) = αTERDR+H + β(TER)2D2R+H . (9)
Comparing equations 7 and 9 shows how the radio-
biological parameters are effectively rescaled by hy-
perthermia to α∗ = αTER and β∗ = βTER2. No-
tably TER has a stronger effect on β∗, bending the
survival curves to lower survival values, in accor-
dance with previous empirical data from experimen-
tal and clinical values studies [16, 37], bending the
survival curves to lower survival values. We propose
a model for TER as a function of HT parameters,
namely temperature and time, which is incorporated
into the LQ-model to predict the survival probabil-
ity of RT combined with mild HT. As detailed in the
results section, TER is assumed to be proportional
to the energy absorbed in the transition from the live
state (A) to the more vulnerable state (A’) EA→A′ ,
which in turn is defined as a rate-limited process
TER ∝ EA→A′ = c1 + c2k(T )t , (10)
where c1 is the baseline of TER, and c2 accounts
for the cell-line specific radio- and thermal sensitiv-
ity. In the absence of hyperthermia TER = 1, re-
sulting in c1 = 1. The transition rate from (A) to
(A’) k(T ) is modelled assuming protein denaturation
as the mechanism responsible for heat-induced cell
damage, as described in the next section.
8Temperature dependence of the transition rate
The temperature dependency of the transition
rate k(T ) is modelled by means of the Eyring’s tran-
sition state theory [42]:
k(T ) =
(
KB
hp
)
Te−
∆G(T )
kBT , (11)
where kB and hp are the Boltzmann and Planck
constants, respectively, and T is the temperature
in Kelvin. We next introduce a suitable model for
the change in Gibbs energy ∆G(T ) consistent with
protein denaturation.
All conformation changes during protein denatu-
ration arise from the competition between formation
and breakage of chemical bonds. Protein denatura-
tion becomes thermodynamically more favourable
with increasing temperature. The dynamics of
protein bonds is quantified by the standard heat of
reaction ∆H0 and the thermal work function ∆W(T )
respectively. We model the mixture of proteins
sensitive to hyperthermia, as an average equivalent
protein. Its overall heat capacity changes as a result
of the state changes of individual proteins within
the mixture. All the ∆ symbols refer to changes in
the thermodynamic properties of this “equivalent”
protein, before and after the transformation.
The energy source for bonds to break is the ther-
mal content
∫ T
T0
Cp(T ′)dT ′, which refers to the heat
absorbed during the process of protein unfolding
while temperature increases. Only a part of the
absorbed heat can be converted into bond-breaking
work, as restricted by the second law of thermody-
namics. The unused proportion of thermal content
goes into entropy –the thermal work– and is propor-
tional to the absorbed heat and the relative temper-
ature increment. The expressions for enthalpy and
work content read as [43]:
∆H(T ) = ∆H0 +
∫ T
T0
Cp(T ′)dT ′,
∆W(T ) =
∫ T
T0
Cp
(T − T ′)
T ′
dT ′, (12)
where ∆H is the enthalpy of the reaction, containing
the bond forming energy ∆H0 and the sum of isother-
mal transfers of heat
∫ T
T0
Cp(T ′)dT ′. Here Cp(T ) is
the heat capacity, which might vary with tempera-
ture, according to the third law of thermodynamics.
The net driving energy is then given by the Gibbs
free energy
∆G(T ) = ∆H0 − ∆W(T ) = ∆H − T∆S (T ), (13)
where ∆S (T ) =
∫ T
0
Cp(T ′)
T ′ dT
′ = ∆S 0 +
∫ T
T0
Cp(T ′)
T ′ dT
′
is the entropy change, with ∆S 0 as reference value.
Accordingly, the Gibbs energy is expressed as
∆G(T ) = ∆G0 +
∫ T
T0
dT ′Cp(T ′)
[
1 − T
T ′
]
, (14)
where ∆G0 = ∆H0 − T∆S 0. The reference tem-
perature can be chosen so that ∆H(T0 = Th) = 0,
∆S (T0 = TS ) = 0, or ∆G(T0 = Tg) = 0. Tg and
Ts are of particular interest since they define the
melting and maximal stability temperatures of the
protein, respectively. When bond formation and
breakage reach a balanced state (∆G(Tg) = 0) the
reaction does not progress anymore. The melting
temperature is defined as the temperature at which
the half of the proteins are denatured [44]. Due to
the importance of protein denaturation, the melting
point is used as the reference temperature from now
on.
The next challenge is to model the heat capacity
in aqueous solutions above physiological tempera-
tures. The heat capacity is expected to increase with
temperature before approaching the vicinity of the
melting point, as a result of ongoing protein recon-
figurations. Beyond the transition, exothermic co-
aggregations of proteins occur and Cp is expected to
decrease due to the reduced degrees of freedom of
more rigid proteins. With these arguments, we pro-
pose to consider the next order by introducing the
heat capacity change as a linear function of (T − Tg)
[34], Cp(T ) = A − B|T − Tg|, which is the same as
Cp(T ) = A + B(T − Tg) for T ≤ Tg, leading to
∆G(T ) = ∆Gc − B2 (T
2 − T 2g ) + BTTg ln
(
T
Tg
)
. (15)
Here ∆Gc, is the usual Gibbs energy resulting from
the assumption of constant heat capacity change. By
introducing Eq.15 in Eq.11, the transition rate for de-
naturation becomes
9k(T ) =
(
KBT
hp
)
e−
∆Gc
KBT e
B
2KB
(T−Tg)
(
1+ TgT
)
. (16)
where the last term in Eq.15 should vanish, because
Tg/T is about one in the Kelvin scale for the hyper-
thermia temperature range (40-50◦C). The first two
factors of Eq.16 slightly change (∼ ±2.5%) in these
regimes, and then the transition rate is dominated by
the exponential behavior. Such exponential behavior
with (T − Tg) has been observed in previous works,
but could not be explained [27, 45]. Based on these
considerations, k(T ) can be described as
k(T ) ≈ c eb(T−Tg), (17)
with c =
(
KBT
hp
)
e−
∆Gc
KBT and b = B2KB as –cell
dependent– adjustable parameters of the model.
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